From the Editors' Desk

Mylan Acquires Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business

Last week Mylan N.V. and Mylan Inc. reported that Mylan has completed the acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business.

Command Medical Promotes Jim Carnall to President

ORMOND BEACH, Fla., Feb. 24, 2015 /PRNewswire/ -- Command Medical Products, premier contract manufacturer of single use disposable plastic medical devices, today announced that Jim Carnall, Chief Operating Officer (COO), has been promoted to...

Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis

NEW BRUNSWICK, N.J., March 2, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced a binding...

GlaxoSmithKline Consumer Healthcare Announces the Return of alli to Retail Stores

PARSIPPANY, N.J., Feb. 25, 2015 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare announced today the return of alli® (orlistat 60 mg capsules) to most stores in the U.S. and Puerto Rico since the voluntary retail recall of the product...

Another Recall Over Potential Sterility Concerns

FDA concerns about aseptic and GMP practices at a manufacturer's site "potentially impacting product sterility" has prompted another recall this week.

Noxilizer RTS Series NO2 Sterilizers Earn CE Mark

Noxilizer Inc. reports that it has been approved for the CE marking of its RTS Series Sterilizers under the Medical Device Directive (MDD). The RTS series use room-temperature NO2 technology in a "rapid process that offers manufacturers...

Time to Apply for Packaging Scholarships

The Institute of Packaging Professionals (IoPP) is announcing the availability of six academic scholarships to students interested in packaging. According to IoPP's Web site, support...

Clear Code adds contrast to traditional coding

3C! Packaging will premiere a sophisticated new coating for coding applications at INTERPHEX NYC 2015, April 21-23 at the Jacob K. Javits Center.  Offering high precision, functionality and consistency...

Great Expectations for Cost-Cutting U.S. Biosimilars but There is a Catch

The imminent approval of the first biosimilars in the U.S. brings widespread optimism that they will stem the tide of soaring specialty drug costs. While biosimilars will yield savings, a new report sponsored by Prime Therapeutics (Prime) cautions...